For clinical application, several strategies have been developed to reduce their renal retention without compromising the tumor uptake, for example, co-injection with gelofusine, lysine or monosodium glutamate to block the binding to megalin, a receptor responsible of the tubular reabsorption of nanobodies (48–50). The gene discussed is LRP2; the disease is neoplasm.